BREAST CANCER CONNECT’s Post

View organization page for BREAST CANCER CONNECT, graphic

909 followers

Polling Q5/5 concludes this incredible 10-day #tutorial journey! What are the 4L treatment choices for ER+/HER2-low mBC patients? Join Dr. Aditya Bardia, one last time, for his response video, analyzing data on #ADCs including the noteworthy DESTINY-Breast04 & TROPICS-02 trials.  A heartfelt thanks to all for your active participation and for following along the hypothetical case of Amber for these 10-days! Special appreciation to Dr. Bardia for his invaluable collaboration. Clinical Takeaways:  1. Elacestrant increases PFS vs. SOC in ESR1m patients, irrespective of PIK3CAm or HER2-low status 2. Hyperglycemiais a target side effect of the PIK3CAi and needs to be monitored closely. 3. T-DXd can be considered in HER2-low mBC post ≥1 line of ChT

To view or add a comment, sign in

Explore topics